NeOnc Technologies Holdings Inc. Common Stock (NTHI)
Stock · NASDAQ · Health Care
$2.72as of 10/16/2026
Price chart
Active signals
NTHI Signal Track Record
How signals performed across all stocks →What NTHI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 6 | -7.7% | 50% | September 8, 2026 |
| Bollinger Band Breakout | 3 | -16.7% | 0% | August 11, 2026 |
| Any 20-session window (baseline) | -12.2% | 34% |
Computed by MarketWall from daily closing prices since January 9, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- neonc.com
Fundamentals
- 1-day range
- $2.67$2.8
- Market cap
- $90.77M
- P/E (trailing)
- —
- P/E (forward)
- -2.52
- EPS (trailing)
- $-1.86
- Dividend yield
- —
- Beta
- 2.74
- Avg. volume
- 196.0K
How NeOnc Technologies Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
NeOnc Technologies Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting Onbenzinga · 10/8/2026
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting OnBenzinga · 10/8/2026
- NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212Yahoo · 9/28/2026
- NeOnc Technologies Schedules FDA In-Person End-of-Phase 1 Type B Meeting Concerning NEO212 For November 17Benzinga · 9/28/2026
- Roth Capital Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20Benzinga · 9/24/2026
- NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential DilutionYahoo · 9/17/2026
- NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a ResultsYahoo · 9/16/2026
- NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/ShrBenzinga · 9/16/2026
Insider Activity
Insider Actions →- Keithly Garnett · September 15, 2026 · Sale5.0K @ $3.36
- Amir F. Heshmatpour · September 15, 2026 · Buy35.0K @ $3.3
- Thomas C. Chen · September 14, 2026 · Buy5.2K @ $3.82
- Keithly Garnett · September 14, 2026 · Buy257 @ $3.89
- Amir F. Heshmatpour · September 14, 2026 · Buy15.0K @ $3.96
- Thomas C. Chen · September 11, 2026 · Buy5.6K @ $3.6
- Amir F. Heshmatpour · September 11, 2026 · Buy37.0K @ $3.67
- Thomas C. Chen · August 18, 2026 · Buy12.8K @ $5.49
- Amir F. Heshmatpour · August 18, 2026 · Buy9.0K @ $5.54
- Thomas C. Chen · August 17, 2026 · Buy2.5K @ $4.04
- Amir F. Heshmatpour · August 17, 2026 · Buy3.0K @ $4.37
- Thomas C. Chen · August 14, 2026 · Buy33.8K @ $3.85
- Amir F. Heshmatpour · August 14, 2026 · Buy12.0K @ $3.79
- Nasim Shomali · July 10, 2026 · Grant50.0K
- Amir F. Heshmatpour · May 1, 2026 · Buy10.0K @ $4.16
Institutional Ownership
March 31, 2026
- Total shares held
- 2.84M
- Total value held
- $19.74M
- Institutional holders
- 24
- Unknown1.43M
- Unknown235.4K
- Unknown215.7K
- Unknown155.8K
- Unknown147.4K
- Unknown126.9K
- Unknown119.2K
- Unknown91.0K
- Unknown51.9K
- Unknown50.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage
NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.
NeOnc Sets FDA Meeting for NEO212; Roth Starts Coverage. NeOnc Technologies has scheduled an in-person FDA End-of-Phase 1 meeting for November 17 regarding its NEO212 candidate. This regulatory milestone provides a clear next step for the company's development timeline. Additionally, Roth Capital initiated coverage with a price target of $20, which is at the top of the current analyst range.